logo-loader
viewEden Research plc

Director/PDMR Shareholding

/**/ link{ color: blue }visited{ color: purple } .ag{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ag{}p.bz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.bx{font-family:"Helvetica Neue"}p.ca{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.cb{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: center}p.cc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; text-align: center}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:115%}span.ce{font-family:"Helvetica Neue";color:black}span.br{font-family:"Helvetica Neue"; color:black} span.bs{font-family:"Helvetica Neue";color:black}span.bq{color:black}span.bp{font-family: "Helvetica Neue"}p.cf{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}table.cg{width:451.3pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.bl{width:4.66%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ch{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold}span.bm{font-size:11.0pt;font-family:"Helvetica Neue"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}td.bk{width:95.34%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt} tr.bg{height:24.95pt}td.bj{width:4.66%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:24.95pt}p.y,li.y,div.y{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}td.bi{width:35.12%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:24.95pt}td.bh{width:60.22%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:24.95pt}td.bf{width:4.66%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.be{width:95.34%;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bd{width:35.12%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bc{width:60.22%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.ci{border-collapse:collapse;border:none} tr.az{height:27.25pt}td.bb{width:110.4pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ba{width:115.4pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ay{width:110.4pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ax{width:115.4pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}span.av{font-family:"Helvetica Neue";color:black; background:white}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;text-align:justify}table.cl{width:459.0pt;margin-left:-10.8pt;border-collapse:collapse}td.ap{width:292.3pt;padding:0cm 5.4pt 0cm 5.4pt} p.cm{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 16.5pt; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.ar{font-size:11.0pt;font-family:"Helvetica Neue"; color:black}td.an{width:145.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.cn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; line-height:16.5pt}span.co{font-size:11.0pt;font-family: "Helvetica Neue";color:black}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:16.5pt}span.cq{font-size:11.0pt;font-family:"Helvetica Neue"}span.cr{font-size:11.0pt;font-family: "Helvetica Neue"}p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.ai{font-size:11.0pt; font-family:"Helvetica Neue";color:black} p.ct{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.cu{font-size:11.0pt;font-family:"Helvetica Neue"; color:black}span.am{font-size:11.0pt;font-family: "Helvetica Neue";color:black}span.ab{}p.ad,li.ad,div.ad{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.ah{font-size:11.0pt;font-family:"Helvetica Neue";color:black} /**/
RNS Number : 1110Q
Eden Research plc
16 October 2019
 

 

 

 

16 October 2019

 

Eden Research plc

 

("Eden" or "Company)

 

 

Director/PDMR Shareholding

 

 

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has today purchased 114,313 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price of 8.3 pence.

 

Following this purchase, Mr Smith holds 547,706 Ordinary Shares representing approximately 0.26 per cent. of the Company's issued share capital. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details of the PDMR dealings set out above.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Mr Sean Smith

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

 

b)

 

LEI

 

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1 pence each in the Company ("Ordinary Shares")

 

GB0001646941

 

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

 

 

 

 

 

c)

 

 

 

 

Price(s) and volume(s)

 

 

 

 

Price(s)

 

Volume(s)

 

8.3 pence

 

114,313

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

N/A (single transaction)

 

e)

 

Date of the transaction

 

16/10/2019

f)

 

Place of the transaction

 

 

LSE, AIM Market (XLON)

 

 

 

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555

 

 

 

Cenkos Securities (Nominated advisor and broker)

 

Giles Balleny / Cameron MacRitchie (corporate finance)
Michael Johnson (sales)

020 7397 8900

 

 

 

Powerscourt (Financial PR)

 

Nick Dibden

 

020 7250 1446

[email protected]

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.  To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

Mevalone is a foliar fungicide which has been authorised for sale in Kenya, Malta, Greece, Bulgaria, 

Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

Cedroz is a nematicide and has been authorised for sale in Malta and Belgium.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

  
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact 
[email protected] or visit www.rns.com.

 

END


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFFMFFMFUSELS

Quick facts: Eden Research plc

Price: 7.85

Market: AIM
Market Cap: £16.26 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Boost for Arkle Resources as Glencore takes stake in partner

Headlines from the Proactive UK newsroom. Irish mining junior Arkle Resources (LON:ARK) has received a boost after mining titan Glencore invested C$1mln into its partner on the Stonepark Zinc Project. Arkle holds a 23.44% stake in Stonepark, which lies to the south of an existing Glencore...

on 16/10/19